Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand? | Zendy

Markus J. Kemper | Zendy; Thomas J. Neuhaus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand?

Author(s) -

Markus J. Kemper,

Thomas J. Neuhaus

Publication year - 2018

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1016/j.kint.2017.09.024

Subject(s) - levamisole , nephrotic syndrome , medicine , steroid , placebo , multicenter trial , multicenter study , randomized controlled trial , pathology , hormone , alternative medicine

Many patients with steroid-sensitive nephrotic syndrome develop a relapsing course; therefore, alternative treatment may be necessary to avoid steroid toxicity. In this issue, a multicenter controlled study in relapsing steroid-sensitive nephrotic syndrome shows the effectiveness of levamisole. Time to first relapse was significantly increased compared with placebo. In addition, possible differential treatment effects were suggested for subgroups: patients with frequent relapses might have a superior response to those with steroid dependency.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research